What is Ability Pharmaceuticals?
Founded in 2009 and headquartered in Cerdanyola del Vallès, Spain, Ability Pharmaceuticals is dedicated to the discovery and development of innovative oncology treatments. The company's core focus lies in its lead candidate, ABTL0812, which is currently undergoing phase 2 clinical trials, alongside the preclinical advancement of ABTL0815. By operating at the intersection of rigorous scientific research and strategic commercial partnerships, such as its territorial licensing agreement with SciClone Pharmaceuticals for the Greater China market, the firm has established a sustainable model for drug development. Its presence within the Parc Tecnològic del Vallès and Parc de Recerca UAB ecosystems facilitates deep collaboration with academic and research institutions, further solidifying its market position as a high-growth entity in the Spanish biotech sector.
How much funding has Ability Pharmaceuticals raised?
Ability Pharmaceuticals has raised a total of $7.6M across 1 funding round:
Other Financing Round
$7.6M
Other Financing Round (2024): $7.6M with participation from The European Innovation Council, The CDTI, Inveready, and CTI Life Sciences Fund
Key Investors in Ability Pharmaceuticals
Inveready
A prominent Spanish financial services firm specializing in alternative investment solutions and wealth management, focusing on small and mid-market segments.
CTI Life Sciences Fund
A Canadian biotech venture capital firm that focuses on catalyzing innovative assets into scalable companies, with a strong emphasis on oncology and rare diseases.
The CDTI
A body of the Spanish General State Administration that supports knowledge-based innovation through subsidies and partially reimbursable aids for R&D projects.
What's next for Ability Pharmaceuticals?
With the recent capital deployment, Ability Pharmaceuticals is poised to prioritize the advancement of its clinical-stage assets, specifically targeting the completion of phase 2 trials for ABTL0812. The strategic roadmap involves not only the acceleration of internal R&D but also the potential for further international licensing agreements to expand the reach of its therapeutic portfolio. As the firm continues to navigate the complexities of drug development, the focus will remain on achieving regulatory milestones and demonstrating the efficacy of its targeted therapies. This phase of growth is critical for the company as it seeks to transition from a research-intensive organization to a commercial-stage biopharmaceutical leader, ultimately aiming to deliver transformative outcomes for patients while maximizing value for its stakeholders.
See full Ability Pharmaceuticals company page
